WO2001000854A3 - Chimeric proteins mediating targeted apoptosis - Google Patents

Chimeric proteins mediating targeted apoptosis Download PDF

Info

Publication number
WO2001000854A3
WO2001000854A3 PCT/GB2000/002449 GB0002449W WO0100854A3 WO 2001000854 A3 WO2001000854 A3 WO 2001000854A3 GB 0002449 W GB0002449 W GB 0002449W WO 0100854 A3 WO0100854 A3 WO 0100854A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric proteins
proteins mediating
apoptosis
targeted apoptosis
mediating targeted
Prior art date
Application number
PCT/GB2000/002449
Other languages
French (fr)
Other versions
WO2001000854A2 (en
Inventor
Peter David Davis
Original Assignee
Angiogene Pharm Ltd
Peter David Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharm Ltd, Peter David Davis filed Critical Angiogene Pharm Ltd
Priority to EP00940615A priority Critical patent/EP1192262A2/en
Priority to AU55527/00A priority patent/AU5552700A/en
Priority to CA002377489A priority patent/CA2377489A1/en
Publication of WO2001000854A2 publication Critical patent/WO2001000854A2/en
Publication of WO2001000854A3 publication Critical patent/WO2001000854A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Chimeric cell-surface proteins are described which may be used in the selective induction of apoptosis in particular target cell types such as cancer cells in vivo or in vitro. Nucleic acid sequences encoding such proteins and methods of use relating to cancer and other therapies are provided.
PCT/GB2000/002449 1999-06-24 2000-06-26 Chimeric proteins mediating targeted apoptosis WO2001000854A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00940615A EP1192262A2 (en) 1999-06-24 2000-06-26 Chimeric proteins mediating targeted apoptosis
AU55527/00A AU5552700A (en) 1999-06-24 2000-06-26 Chimeric proteins mediating targeted apoptosis
CA002377489A CA2377489A1 (en) 1999-06-24 2000-06-26 Chimeric proteins mediating targeted apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914650.8A GB9914650D0 (en) 1999-06-24 1999-06-24 Chimeric proteins mediating targeted apoptosis
GB9914650.8 1999-06-24

Publications (2)

Publication Number Publication Date
WO2001000854A2 WO2001000854A2 (en) 2001-01-04
WO2001000854A3 true WO2001000854A3 (en) 2001-07-05

Family

ID=10855886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002449 WO2001000854A2 (en) 1999-06-24 2000-06-26 Chimeric proteins mediating targeted apoptosis

Country Status (5)

Country Link
EP (1) EP1192262A2 (en)
AU (1) AU5552700A (en)
CA (1) CA2377489A1 (en)
GB (1) GB9914650D0 (en)
WO (1) WO2001000854A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP2102234A2 (en) 2006-11-28 2009-09-23 GHC Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
EP2566887A1 (en) * 2010-05-05 2013-03-13 Addex Pharma SA Chimeric receptors and methods for identifying agents exhibiting an activity on type 1 single pass transmembrane receptors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201506223D0 (en) * 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013210A1 (en) * 1991-12-20 1993-07-08 Bristol-Myers Squibb Company Icams immunoglobulin constant region soluble fusion proteins
WO1995002684A1 (en) * 1993-07-16 1995-01-26 The Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013210A1 (en) * 1991-12-20 1993-07-08 Bristol-Myers Squibb Company Icams immunoglobulin constant region soluble fusion proteins
WO1995002684A1 (en) * 1993-07-16 1995-01-26 The Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LI RUIHONG ET AL: "Chimeric CD4/CD44 molecules associate with CD44 via the transmembrane region and reduce hyaluronan binding in T cell lines.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 6, June 1998 (1998-06-01), pages 1745 - 1754, XP000953332, ISSN: 0014-2980 *
MA J ET AL: "Second generation apoptotic-induced drug delivery system based on cells that express a flk-1:fas fusion protein.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 277, XP000971899, ISSN: 0197-016X *
NAOR D ET AL: "CD44:STRUCTURE, FUNCTION, AND ASSOCIATION WITH THE MALIGNANT PROCESS", ADVANCES IN CANCER RESEARCH,ACADEMIC PRESS, LONDON,GB, vol. 71, 1997, pages 241 - 319, XP000952636, ISSN: 0065-230X *
RAFFIONI SIMONA ET AL: "Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells: A model for the control of receptor tyrosine kinase activation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 52, 25 December 1998 (1998-12-25), pages 35250 - 35259, XP002157209, ISSN: 0021-9258 *
RUDERT F ET AL: "APOPTOSIS IN L929 CELLS EXPRESSING A CD40/FAS CHIMERIC RECEPTOR: DISSOCIATION OF STIMULATORY FROM INHIBITORY DEATH SIGNALLING FUNCTIONS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 204, no. 3, 15 November 1994 (1994-11-15), pages 1102 - 1110, XP002070355, ISSN: 0006-291X *
RUDERT FRITZ ET AL: "Apoptosis through CD95 (Fas/APO-1), but not a CD40/CD95 chimeric receptor, is inhibited by phorbol-12-myristate-13-acetate.", DNA AND CELL BIOLOGY, vol. 16, no. 2, 1997, pages 197 - 205, XP000978716, ISSN: 1044-5498 *
UENO HIROO ET AL: "An epidermal growth factor receptor-leukocyte tyrosine kinase chimeric receptor generates ligand-dependent growth signals through the Ras signaling pathway.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 34, 1995, pages 20135 - 20142, XP002157210, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2377489A1 (en) 2001-01-04
WO2001000854A2 (en) 2001-01-04
GB9914650D0 (en) 1999-08-25
AU5552700A (en) 2001-01-31
EP1192262A2 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
WO2004063362A3 (en) Cell cycle progression proteins
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
AU4981101A (en) Subtilisin variants
WO2002036743A3 (en) Antisense modulation of calreticulin expression
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
AU2001290706A1 (en) Antisense modulation of clusterin expression
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
AU2001294943A1 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2001059459A3 (en) Compositions and methods for screening therapeutic agents
WO2005000240A3 (en) Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
WO2003076561A3 (en) Recombinase fusion protein with enhanced cellular uptake
WO2005120588A3 (en) Peptides delivered to cell nuclei
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2001000854A3 (en) Chimeric proteins mediating targeted apoptosis
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
AU2002364302A1 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO1999047655A3 (en) Human nucleic acid fragments with heightened expression in normal breast tissue
WO2000008157A3 (en) Human anion transporter genes atnov
PT1140023E (en) INTEGRATING COCLEAR FORMULATIONS OF PROTEIN-DNA AND METHODS OF CELLULAR TRANSFORMATION
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
AUPR721101A0 (en) Nucleic acid and polypeptide linked to breast cancer
WO2001043694A3 (en) Compositions and methods for caspase-induced apoptosis
MXPA03003983A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids.
WO2001036478A3 (en) Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2377489

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000940615

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000940615

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10018826

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000940615

Country of ref document: EP